Abstract 1497P
Background
Resuscitation decisions in cancer patients continue to challenge Healthcare Professionals (HCPs) and often do not take place until clinical deterioration, risking futile Cardiopulmonary Resuscitation (CPR) attempts. This research investigated outcomes of In-Hospital Cardiopulmonary Arrest (IHCA) in advanced cancer within an NHS Trust in the UK, alongside viewpoints of HCPs.
Methods
This mixed-methods study comprised two components. Retrospective data analysis examined IHCA outcomes in patients with advanced cancer in Newcastle upon Tyne Hospitals NHS Foundation Trust (NUTH) between 2012-2022. Main outcomes included rate of Return of Spontaneous Circulation (ROSC) and survival to discharge. Other outcomes were median overall and post-discharge survival. A survey was distributed to senior HCPs in Acute Medicine (AM), Emergency Medicine (EM) and Oncology, to establish perceptions of CPR success in advanced cancer, and gather current opinion on issues surrounding resuscitation in this context.
Results
Among 83 patients, rate of ROSC was 33.7% and 9.6% survived to discharge. Among survivors, median overall survival was 2 days, and post-discharge survival 391 days. 92 HCPs responded to the survey. The mean likelihood of a patient with advanced cancer achieving ROSC was estimated at 13.4%. Oncologists were ranked the most appropriate HCP to discuss resuscitation, and outpatient clinic appointments the most suitable place. From analysis of text comments, important themes were (1) Place, person and timing, (2) Individualised decision-making, and (3) Improving patient understanding.
Conclusions
Survival following CPR is poor in advanced cancer, and fewer than 10% patients in this study gained any meaningful survival benefit. A collective approach is needed from HCPs to integrate personalised discussions about future care and resuscitation into routine cancer management. These should begin early rather than at a time of crisis, with someone the patient trusts. Blanket decisions are not suitable for any patient and cannot supersede clinical judgement alongside assessment of patient priorities and values.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Newcastle Hospitals Charity.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1554P - Co payments in cancer patients: Analysis and estimating OOP
Presenter: Krishnamani Kalpathi
Session: Poster session 10
1555P - Estimating the social value of immuno-oncology (IO) therapies in Japan
Presenter: Tomoya Ohno
Session: Poster session 10
1556P - Current landscape of drug approvals for genitourinary (GU) cancers in North America and Europe
Presenter: Jose Tapia
Session: Poster session 10
1557P - The use of patient experience in UK NICE decision making in oncology
Presenter: Noemi Muszbek
Session: Poster session 10
1558P - Independent validation of the Breast Cancer Risk Assessment Tool (Gail model) for predicting breast cancer risk in Egyptian population
Presenter: Elaria Yacoub
Session: Poster session 10
1559P - Equity of access and clinical impact of genomic testing in patients with cancer in a UK early phase clinical trials unit
Presenter: Jonathan Poon
Session: Poster session 10
1560P - Optimal age versus real age in breast and gynaecological risk reducing surgery in BRCA1/2 carriers
Presenter: Alberta Ferrari
Session: Poster session 10
1561P - Targeted screening methodologies to select high risk individuals: LungFlag performance in Estonia Lung Cancer Screening Pilot
Presenter: Tanel Laisaar
Session: Poster session 10
1562P - The feasibility of polygenic risk score-based population screening for breast cancer: The experience from the BRIGHT study in Estonia
Presenter: Anni Lepland
Session: Poster session 10
1563P - Increasing the earlier detection of lung cancer: A toolbox for change
Presenter: Helena Wilcox
Session: Poster session 10